Citigroup
KYNB

Citigroup’s Kyntra Bio KYNB Stock Holding History

Citigroup’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,888
Closed -$108K – 5707
2023
Q4 		$108K Sell
4,888
-376
-7% -$5.67K ﹤0.01% 4173
2023
Q3 		$114K Buy
5,264
+1,632
+45% +$64.1K ﹤0.01% 3884
2023
Q2 		$245K Buy
+3,632
New +$1.5M ﹤0.01% 3793
2023
Q1 		– Sell
-2,400
Closed -$961K – 5613
2022
Q4 		$961K Sell
2,400
-2,300
-49% -$881K ﹤0.01% 2630
2022
Q3 		$1.53M Buy
4,700
+1,200
+34% +$386K ﹤0.01% 2358
2022
Q2 		$924K Buy
+3,500
New +$894K ﹤0.01% 2725

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citigroup's KYNB Position: Q2 2026 in Review

Citigroup sold out of Kyntra Bio (KYNB) in Q2 2026, closing a stake of 1 share — an estimated $7 sold.

Citigroup first reported a position in KYNB in Q4 2014 and held it in 43 quarters. The position peaked at $11.1M in Q1 2023. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • Citigroup reported no remaining Kyntra Bio position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Kyntra Bio share in Q2 2026, an estimated $7.
  • Citigroup first reported a position in Kyntra Bio in Q4 2014 and held it in 43 quarters.
  • Citigroup's Kyntra Bio position peaked at $11.1M in Q1 2023.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.